9.36
前日終値:
$9.05
開ける:
$9.07
24時間の取引高:
1.20M
Relative Volume:
1.47
時価総額:
$525.77M
収益:
$8.78M
当期純損益:
$-104.70M
株価収益率:
-3.9494
EPS:
-2.37
ネットキャッシュフロー:
$-82.68M
1週間 パフォーマンス:
-2.80%
1か月 パフォーマンス:
+45.57%
6か月 パフォーマンス:
-32.56%
1年 パフォーマンス:
-22.06%
Stoke Therapeutics Inc Stock (STOK) Company Profile
STOK を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
STOK
Stoke Therapeutics Inc
|
9.36 | 525.77M | 8.78M | -104.70M | -82.68M | -2.37 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
2024-10-14 | 再開されました | Leerink Partners | Outperform |
2024-03-26 | アップグレード | TD Cowen | Market Perform → Outperform |
2023-11-20 | 再開されました | JP Morgan | Neutral |
2023-07-25 | ダウングレード | TD Cowen | Outperform → Market Perform |
2023-05-01 | アップグレード | BofA Securities | Underperform → Neutral |
2023-04-26 | 再開されました | Canaccord Genuity | Buy |
2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
2022-10-24 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2022-01-31 | 開始されました | Jefferies | Buy |
2021-12-03 | 開始されました | BofA Securities | Buy |
2021-11-22 | アップグレード | JP Morgan | Neutral → Overweight |
2021-05-18 | 開始されました | UBS | Neutral |
2021-05-10 | アップグレード | Wedbush | Neutral → Outperform |
2021-04-26 | 再開されました | Credit Suisse | Outperform |
2021-02-10 | ダウングレード | Wedbush | Outperform → Neutral |
2020-12-15 | 再開されました | H.C. Wainwright | Buy |
2020-12-11 | 繰り返されました | Needham | Buy |
2020-10-23 | 開始されました | Cantor Fitzgerald | Overweight |
2020-09-29 | 再開されました | JP Morgan | Neutral |
2020-09-29 | 開始されました | Needham | Buy |
2019-12-18 | 開始されました | Wedbush | Outperform |
2019-11-12 | 開始されました | BTIG Research | Buy |
2019-10-25 | 開始されました | H.C. Wainwright | Buy |
2019-07-15 | 開始されました | Canaccord Genuity | Buy |
2019-07-15 | 開始されました | Cowen | Outperform |
2019-07-15 | 開始されました | Credit Suisse | Outperform |
2019-07-15 | 開始されました | JP Morgan | Overweight |
すべてを表示
Stoke Therapeutics Inc (STOK) 最新ニュース
Wells Fargo & Company MN Has $185,000 Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Invesco Ltd. Takes Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Form DEF 14AOther definitive proxy statements - ADVFN
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Monday - Defense World
Technical analysis of Stoke Therapeutics Inc (STOK) stock chart patterns - uspostnews.com
Biogen tops estimates on rare disease strength, cuts full-year guidance - The Pharma Letter
Biogen lowers annual earnings outlook, surpasses Q1 estimates By Investing.com - Investing.com Canada
Legal & General Group Plc Decreases Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Market Momentum Report: Stoke Therapeutics Inc (STOK)’s Negative Close at 9.47 - DWinneX
Renaissance Technologies LLC Invests $1.42 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Market Highlights: Stoke Therapeutics Inc (STOK) Ends on a High Note at 9.52 - DWinneX
Stoke Therapeutics Inc (STOK) deserves deeper analysis - uspostnews.com
Geode Capital Management LLC Purchases 6,264 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock? - MSN
Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock? - NewsBreak: Local News & Alerts
Stoke Therapeutics Inc (STOK) rating initates by Chardan Capital Markets - knoxdaily.com
(STOK) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Leerink Partnrs Issues Optimistic Estimate for STOK Earnings - Defense World
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be - simplywall.st
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of “Buy” by Analysts - Defense World
Vanguard Group Inc. Sells 28,049 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Wellington Management Group LLP Has $1.49 Million Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Needham & Company LLC Reiterates Buy Rating for Stoke Therapeutics (NASDAQ:STOK) - Defense World
Needham Keeps Their Buy Rating on Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - simplywall.st
Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges By Investing.com - Investing.com South Africa
Stoke Therapeutics stock hits 52-week low at $6.09 amid market challenges - Investing.com India
Teacher Retirement System of Texas Purchases Shares of 10,219 Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire
Revolutionary RNA Treatment for Rare Disease: Stoke CEO to Reveal Latest Progress - Stock Titan
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential - TradingView
Swiss National Bank Acquires 11,400 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
FY2025 Earnings Forecast for STOK Issued By Chardan Capital - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges By Investing.com - Investing.com South Africa
Stoke Therapeutics stock hits 52-week low at $7.20 amid market challenges - Investing.com Australia
Dravet Syndrome Market Expected to Experience Major Growth - openPR.com
Bank of New York Mellon Corp Acquires 1,330 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
(STOK) Technical Data - news.stocktradersdaily.com
Cantor Fitzgerald Issues Positive Forecast for STOK Earnings - Defense World
Wedbush Equities Analysts Raise Earnings Estimates for STOK - Armenian Reporter
Earnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo
Stoke Therapeutics Inc (STOK) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):